Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980235 | 0.91 | ADORA2A (0.72) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL19851461 | 0.89 | ADORA2A (0.69) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3421554 | 0.89 | RAB9A (0.66) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL18057705 | 0.87 | ADORA2A (0.65) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL18057707 | 0.85 | ADORA2A (0.69) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL9566496 | 0.85 | RAB9A (0.61) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL671052 | 0.85 | RAB9A (1.00) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL670606 | 0.85 | RAB9A (0.61) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL29803065 | 0.85 | RAB9A (0.61) | RAB9AADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL27595066 | 0.85 | RAB9A (0.61) | RAB9AADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4672083-A | USING 4,6-DIAMINO-1,3,5-TRIAZIN-2-YL COMPOUND AS FORMALDEHYDE BINDING AGENT | DEGUSSA AG (DE) | 1987-06-09 | — | — | US | claimed |
| CN-116284634-A | Preparation method of high-stability polymer used as anode material of lithium ion battery | 安徽大学 | 2023-06-23 | — | — | CN | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7390847-B2 | Polymer derivatives for the treatment of metals | BASF SE (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20050121114-A1 | Polymer derivatives for the treatment of metals | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1470198-A2 | POLYMER DERIVATIVES FOR THE TREATMENT OF METALS | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003056061-A2 | POLYMER DERIVATIVES FOR THE TREATMENT OF METALS | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0202530-B1 | OXYMETHYLENE COPOLYMER MOULDING COMPOSITIONS HAVING A REDUCED EMISSION OF FORMALDEHYDE DURING THERMOPLASTIC PROCESSING | Degussa Aktiengesellschaft (DE) | 1990-09-12 | — | — | EP | disclosed |
| US-4672083-A | USING 4,6-DIAMINO-1,3,5-TRIAZIN-2-YL COMPOUND AS FORMALDEHYDE BINDING AGENT | DEGUSSA AG (DE) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | RAB9A 1744/4885ADORA2A 1687/4885ADORA1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.